NPPA newly fixed or revised the prices of 169 formulation packs

The National Pharmaceutical Pricing Authority (NPPA) has newly fixed or revised the prices of 169 formulation packs including the maximum retail price of some of the products with Pfizer India, Novartis India and Alcon Laboratories. The authority has also revised the price fixed for five bulk drugs through another notification.

The prices of five bulk drugs, ibuprofen, ibuprofen sodium, ibuprofen lysinate and S(+) Ibuprofen or dexibuprofen and ranitidine HCl were fixed, which shall become effective within 15 days from the date of notification in the official Gazette.

The ceiling prices for the formulation packs including doxycycline hyclate with combination, dexibuprofen, chlorpromazine and its combination, spironolactone with combintion, dexibuprofen with paracetmaol, prednisolone, trimethoprim with sulfamethoxazole, oxytetracycline, oxytetracycline with vitamin, dextropropoxyphene with combination, spironolactone with combintion, multivitamin with lycopene, norfloxacin with combination, ciprofloxacin with combination, silver sulfadiazine with combination, metrondiazole benzoate, metronidazole with furazolidone, metronidazole with norfloxacin, trimethoprim with sulfamethoxazole, among others, has been revised through the notification.

Further, maximum retail prices were revised and increased for Vitalux Plus TR manufactured or imported by Novartis India Ltd, prednisolone acetate ophthalmic manufactured or imported by Alcon Lab (India) Pvt Ltd, Medrol, Solu-medrol, Depo Medrol and Daivobet 15 gm tube manufactured or imported by Pfizer Products India Pvt Ltd.

The prices fixed or revised shall be made effective within 15 days of receipt of the order, added the NPPA notification.